Capital Fund Management (CFM)
SWTX

Capital Fund Management (CFM)’s SpringWorks Therapeutics SWTX Stock Holding History

Capital Fund Management (CFM)’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-66,840
Closed -$1.91M – 1627
2022
Q3 		$1.91M Buy
+66,840
New +$1.92M 0.02% 872

Other funds holding SWTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Capital Fund Management (CFM)'s SWTX Position: Q4 2022 in Review

Capital Fund Management (CFM) sold out of SpringWorks Therapeutics (SWTX) in Q4 2022, closing a stake of 66,840 shares — an estimated $1.91M sold.

Capital Fund Management (CFM) first reported a position in SWTX in Q3 2022 and held it in 1 quarter. The position peaked at $1.91M in Q3 2022. 137 funds tracked by Wall St. Rank hold SWTX as of Q4 2022.

  • Capital Fund Management (CFM) reported no remaining SpringWorks Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 66,840 SpringWorks Therapeutics shares in Q4 2022, an estimated $1.91M.
  • Capital Fund Management (CFM) first reported a position in SpringWorks Therapeutics in Q3 2022 and held it in 1 quarter.
  • Capital Fund Management (CFM)'s SpringWorks Therapeutics position peaked at $1.91M in Q3 2022.
  • 137 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q4 2022.

Based on Capital Fund Management (CFM)'s 13F filing for Q4 2022, filed 13 Feb 2023.